Refine by
Vascularized Tissue Articles & Analysis
11 news found
These new Circulatory System Tissue Microarrays, including Heart & Vascular Tissue Microarrays and Spleen Tissue Microarrays, are designed to accelerate research into heart disease, vascular disorders, and other conditions affecting the circulatory system. ...
HyStem is a patented hydrogel which mimics naturally occurring extracellular matrix, the structural network of molecules surrounding cells in organs and tissues and essential to cellular function and tissue structure. HyStem biomaterial has been shown to support cellular attachment and survival as well as compatibility with a wide variety of cells and ...
About SANUWAVE Health SANUWAVE Health (OTCQB: SNWV) is focused on the research, development, and commercialization of its patented, Energy First non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE's end-to-end wound care portfolio of regenerative ...
These latest imaging biomarkers strengthen VIDA’s portfolio of airway, tissue, vascular and functional measures. VIDA’s latest airway biomarkers include mucus plug scoring, bronchiectasis scoring, and total airway count (TAC). ...
The patent has 20 claims and will expire on November 14, 2037. EP 3285661 titled "Tissue Disinfection with Acoustic Pressure Shock Waves", with the United Kingdom, France, Germany, and Netherland as designated countries. This patent covers the methods and device embodiments that use extracorporeal acoustic pressure shock waves for preventing and treating living ...
” About SANUWAVE SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE’s end-to-end wound care portfolio of regenerative medicine products and ...
” About SANUWAVE SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE’s end-to-end wound care portfolio of regenerative medicine products and ...
The allowed DuraGraft® related patent applications cover an organ and tissue preservation kit containing shelf-life stable solutions used for vascular graft and tissue protection and preservation during bypass and other vascular surgeries. These patents protect Marizyme’s flagship commercial product DuraGraft®, a ...
(OTCQB: SNWV), focused on the development and commercialization of a robust and innovative advanced wound care product portfolio for the repair and regeneration of skin and vascular structures, today announced its rebranding. The new brand reflects the evolution of SANUWAVE’s solutions addressing the entire wound care pathway through its portfolio of noninvasive and ...
This collaboration builds on the existing partnership between the two companies and will see the combining of Aspect’s proprietary microfluidic 3D bioprinting platform with JSR’s advanced materials technology to develop implantable vascularized tissues for kidney regeneration and other applications in regenerative medicine. The ...
(OTCQB: SNWV), focused on the development and commercialization of a robust and innovative advanced wound care product portfolio for the repair and regeneration of skin and vascular structures, announced today that the Company has entered into a non-exclusive sales and marketing agreement with Ametus to market and sell the Company’s portfolio of wound care products in the ...